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Abstract Dose–response curves for inhibitors (drugs) gener-
ally are analyzed by means of four-parameter fits, yielding
IC50, background, amplitude, and Hill coefficient. Hill
coefficients ≠1 contradict 1:1 competition. If binding of
substrates to proteins is a stepwise process where initial
binding to initial locations (patches) leads to strong binding
on defined sites, then drugs (non-endogenous inhibitors) may
bind to those presumably larger patches and need not follow a
1:1 stoichiometry for specific inhibition. This concept was
translated into three computable models and successfully
fitted to 1,282 phosphatase dose–response curves. The models
only required four parameters, namely, the equilibrium
dissociation constant KD(1) of the first inhibitor binding step,
background, amplitude, and a compound interaction factor to
quantify the interaction of inhibitors on those patches.
Binding of one established inhibitor to the vaccinia virus
VH1-related (VHR) phosphatase was directly measured with
microcalorimetry, confirming multiple inhibitor binding with
equilibrium constants obtained from corresponding inhibition
curves.
Keywords Dose–responsecurves.Hillcoefficients.
Enzymaticactivity.Ligandbinding
Introduction
Drug development [1] typically involves screening of large
compound libraries [2]. Those compounds which display
significant inhibition in one or more significant cellular or
biochemical assays are identified as hits; their potencies are
given as IC50 values. These are the concentrations of
compounds required to inhibit an activity or other signal in
a given assay by 50%. In most cases, IC50 values are
derived from four-parameter fits (4PL) [3, 4] of enzymatic
activity measured as a function of inhibitor concentration
I0:
Activity ¼ Min þ Max   Min ðÞ
.
1 þ I0=IC50 ðÞ
slope
  
ð1Þ
This yields a symmetric sigmoid curve when activity is
plotted versus the logarithm of I0. The four parameters
derived from a fit of that curve to experimental data are
Min and Max for background and 100% activity, IC50 for
the inflection point, and slope as a measure for the maximal
slope in the half logarithmic sigmoid representation. These
four parameters are statistically not correlated and therefore
ideal for data fitting. For I0=IC50, Activity is equal to Min+
(Max−Min)/2, as expected and indicated by the name.
The molecular interpretation of 4PL curves has always
been a problem [5]. If the response is proportional to
compound binding [6], Eq. 1 would correspond to
simultaneous binding of n agonist molecules (A)t oa
receptor (R):
n   A þ R !   AnR ð2Þ
With the exception of n=1, this scheme is not plausible [5]
since it postulates the simultaneous binding of n molecules
without intermediates such as A1R, A2R, A3R….W h e nE q .1
is applied for the calculation of reaction scheme 2, the
parameter slope corresponds to the number n of molecules A
in scheme 2. This parameter is called Hill coefficient nH.
Fitting real data yields non-integer slopes, but non-integer nH
J Chem Biol (2008) 1:95–104
DOI 10.1007/s12154-008-0011-5
Electronic supplementary material The online version of this article
(doi:10.1007/s12154-008-0011-5) contains supplementary material,
which is available to authorized users.
H. Prinz (*):A. Schönichen
Max-Planck-Institut für Molekulare Physiologie,
Otto-Hahn-Str. 11,
44227 Dortmund, Germany
e-mail: heino.prinz@mpi-dortmund.mpg.dedoes not conform to scheme 2. Hill coefficients usually are
regarded as an indication for the lower limit of the number of
interacting small molecules on a receptor. For nH>1, the
corresponding binding curve would be sigmoid and indica-
tive of a “cooperative” binding mechanism.
To our best of knowledge, most experimental dose–
response curves obtained from high throughput screens yield
varying Hill coefficients, independent of the assay or the
compound library. And conversely, variations in Hill coef-
ficientsarethe underlyingreasonfor four-parameterfits,since
true 1:1 competition could be fitted with three parameters.
Publication of absolute IC50 measurements [7, 8]a v o i d s
commitment to a nonplausible molecular mechanism but
does not explain the underlying binding process. This
contribution now will address possible molecular mecha-
nisms leading to Hill coefficients other than one. It will
employ these mechanisms to fitting a consistent body of
inhibition experiments. Although only enzymes, substrates
and inhibitors have been measured, the underlying mecha-
nisms are of general interest for pharmacology where one
traditionally considers receptors, agonists, and inhibitors.
Therefore, the general symbol A (“Agonist”)w i l la l s od e n o t e
substrate, and the general symbol R (“Receptor”)w i l la l s o
stand for enzymes used in competition assays.
Materials and methods
All phosphatase assays were performed by means of
automated systems consisting of Tecan EvoWare robots
and Genios Pro MTP readers. The twofold dilution series
were obtained from 10 μl of a buffered enzyme solution
containing 200 μM of inhibitor. Of this, 5 μl was removed
and mixed with 5 μl buffered enzyme solution resulting in a
twofold dilution. This step was repeated nine times. Five
microliters of the final dilution was removed, so that 11
wells consisted of 5 μl buffered enzyme with twofold
inhibitor dilutions. The last two columns were left for
controls. After a pre-incubation period of 10 min, the
reaction was started by the addition of 5 μl p-nitrophenyl
phosphate. This gave a reaction volume of 10 μl and
inhibitor concentrations of 100, 50, 25… μM. All experi-
ments were performed in quadruplicates with eight different
inhibitors on one 384 microtiter plate. Reaction velocity
was determined from the slope of the absorbance change of
the substrate (p-nitrophenyl phosphate) at 405 nm and
related to control without enzyme for 0% activity and
without inhibitor for 100% activity. The substrate concen-
tration was 50 mM in the case of CDC25A, 5 mM in the
case of vaccinia virus VH1-related (VHR) phosphatase, and
1 mM for all other phosphatases; the reactions were
observed at 405 nm in a spectrophotometer kept at 37 °C.
These relatively high concentrations were chosen to be
between two- and threefold above the respective Km values
[9]. For all enzymes, their concentration was adjusted to an
initial absorbance change between 0.5 and 1 OD405 during
the measuring time of 30 min.
Epigallocatechin-3-monogallate (compound 172) was
obtained from Microsource Discovery; bis(4-trifluorome-
thylsulfonamidophenyl)-1,4-diisopropylbenzene (com-
pound 281, also named “Protein Tyrosine Phosphatase
Inhibitor IV,” which was routinely run as standard in all
plates) was obtained from Calbiochem CAT# 540211.
The phosphatases PTP1b, MPTPA, MPTPB, and SHP2
were donated from Prof. Schwalbe, Frankfurt. The phos-
phatases VHR and CDC25A were produced by Kirill
Alexandrov, Max-Planck-Institute Dortmund. Vascular en-
dothelial protein tyrosine phosphatase (VE-PTP) was a gift
from Prof. Vestweber, Max-Planck-Institute Münster. All
reaction mixtures contained 1 mM 1,4-dithio-D,L-threitol
(DTE; added on the day of the experiment from 100 mM
stock) and 0.0125% (v/v) of the detergent NP-40 (Calbio-
chem 492015). The buffers consisted of 50 mM Tris,
50 mM NaCl, 0.1 mM ethylenediamine tetraacetic acid
(EDTA), pH 8.0 in the case of CDC25A; or 25 mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES),
50 mM NaCl, 2.5 mM EDTA, pH 7.2 in the case of
PTP1b, SHP2, MPTPA, and MPTPB; 50 mM Tris, 50 mM
NaCl, 0.1 mM EDTA, pH 8.0, 40 mM Tris, 30 mM MgCl2,
20 mM KCl, pH 8.1, or 25 mM 3-(N-morpholino)propane-
sulfonic acid, 5 mM EDTA, pH 6.5 in the case of VHR.
Isothermal Titration Calorimetry The thermodynamic
parameters of the VHR phosphatase interaction with com-
pound 281 were determined by isothermal titration calorim-
etry (ITC; VP-ITC, MicroCal). Purified VHR phosphatase
was diluted to a concentration of 25 μMi nI T Cb u f f e r
[50 mM HEPES, pH 7.4, 40 mM NaCl, 1 mM EDTA, 1 mM
DTE, 0.025% NP-40, 1% dimethyl sulfoxide (DMSO)] and
thermostated in the sample cell at 15 °C, 25 °C, and 37 °C,
respectively. The inhibitor was solubilized with DMSO to a
concentration of 100 mM and diluted with ITC buffer
without DMSO in 1:100 ratio. This solution was injected
stepwise by volumes of 8 μl from syringe into sample cell
containing the phosphatase solution. Control measurements
where performed by injecting inhibitor into buffer without
phosphatase. The change in heating power was observed for
4 min until equilibrium was reached before the next injection
was started. The control data were subtracted from the
binding data to deplete data from injection effects. Further
data evaluation was performed using the manufacturer’s
analysis software, yielding equilibrium constants and ΔH°
values.
For model calculations, three non-linear equations
follow from the summation of total enzyme, total substrate,
and total inhibitor concentration and the complexes
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complexes were calculated from the free concentrations
and the respective equilibrium dissociation constants, e.g.,
ARI2 ¼ A   R   I   I= KD   KI 1 ðÞ   KI 2 ðÞ ðÞ . The result-
ing three equations only have three unknowns, namely, the
free concentrations A, R,a n dI. All calculations were done
with the program Matlab R2007b and its optimization
toolbox (Mathworks.com). The routine fsolve was employed
for solving the set of non-linear equations, and lsqcurvefit
was used for multiparameter nonlinear fits. For inhibition
experiments, only the ratio of substrate concentration to Km
value is relevant for the calculation of complexes. Since the
experiments were performed at A0/Km of roughly a factor 2
[9], a total substrate concentration of 100 μMa n daKm value
of 50 μM could be used for the calculation of all
experiments alike. Likewise, for all experiments, the total
enzyme concentration R0 was set to 0.01 μM, i.e., one order
of magnitude lower than the lowest inhibitor concentration.
This ensured that both relations, A0/R0 and I0/R0,w e r e
10,000 or less, and therefore, numerical rounding artifacts
were avoided. Fitting routines require initial parameters,
which were set to 10 μM for all equilibrium inhibition
dissociation constants and 1 for the compound interaction
factor CIF (Eq. 7) and the Hill coefficient. The lower limit of
these parameters was set to 0.001, the lower limit for Min to
20%, and the lower limit for Max to 60%. The residual sum
of squares (the value of the squared 2-norm of the residual)
was returned from the function lsqcurvefit, which also was
employed for 4PL fitting (Eq. 1). This sum of squares is a
measure for the goodness of fit and should be as low as
possible.
Correlation coefficients of the resulting parameters were
calculated with the program Benchware Data Miner,
version 1.6 (Tripos L.P.). This program was also employed
to calculate the molecular properties (AlogP98, polarizabil-
ity, pLC50, volume, hydrogen bond donors, hydrogen bond
acceptors, and rings) of the compounds.
The qualityofthe fitscouldonlybecomparedwithrelative
residuals, since absolute residuals also reflect the noise of
single experiments. For this, noisy experiments (Z′-factor
<0.5)[10] or experiments with fits out of range (Min<−19%,
Max<61%) were discarded. Having sorted the residuals
according to their 4PL Hill coefficient, their values were
replaced by the average of next ±3 neighbors (non-biased
noise-filter with n=7). Then relative residuals were calculat-
ed in relation to the 4PL residuals. Eleven of the resulting
1,138 experiments had relative residuals of model C6>350
for nH>1. These experiments also were discarded, so that
1,127 experiments were finally selected for the calculations
shown in Fig. 3. One note on errors: Errors which can be
obtained from curve-fitting algorithms generally differ from
experimental errors. This is the reason why errors for single
fits are only given in the supplementary material and only for
Fig. 5. Variations of repeated experiments [indicated by
Quad(rant) 1 to 4 for the same enzyme and compound
number] are more significant and are shown in table
FitANCH6 of the supplementary material.
Results
Classical description of inhibition curves by means
of four-parameter fits
The enzymatic activities of the phosphatases MPTPA,
MPTPB, CDC25A, PTP1b, VHR, VE-PTP and SHP2 were
analyzed after addition of 280 different selected com-
pounds. For each of these compounds, dilution series (11
concentrations, differing by a factor 2 each) were performed
in quadruplicates. That gave a body of 7,840 individual
inhibition curves measured between 0.1 and 100 μMo f
inhibitor. Of these, 1,282 experiments showed IC50 values
between 0.5 and 25 μM and thus were ideal for the
concentration range of the experiments.
Figure 1 shows a dot plot of IC50 values and Hill
coefficients nH obtained from 4PL (Eq. 1) fits of these
experiments. Two features are noteworthy: (1) The distri-
butions for IC50 are not correlated to the distributions of nH.
(2) The distributions of Hill coefficients nH depend on the
enzyme investigated. For example, the phosphatase VE-
PTP showed the largest variety in the slopes of inhibition
curves with Hill coefficients ranging from 0.3 to 6.8 (factor
0
5
10
15
20
25
I
C
5
0
 
(
µ
M
)
Hill Coefficient
 CDC25a
 MPTPA
 MPTPB
 PTP1b
 SHP-2
 VE-PTP
 VHR
01234567
Fig. 1 IC50 versus the Hill coefficient derived from four-parameter
fits (Eq. 1). Two hundred eighty substances were tested for their
inhibition of seven phosphatases (CDC25a, MPTPA, MPTPB, PTP1b,
SHP-2, VE-PTP, and VHR) in quadruplicates. Only experiments with
IC50 values between 0.5 and 25 μM are shown. Hill coefficients are a
measure of the steepness (slope) of dose–response curves (Fig. 3). The
IC50 value is the inhibitor concentration, where 50% of activity is
maintained
J Chem Biol (2008) 1:95–104 9722). More than 57% of all Hill coefficients were either
lower than 0.7 or larger than 1.3. Thus, a large proportion
of the experiments of Fig. 1 clearly did not conform to 1:1
inhibition which should always give a Hill coefficient of
one. A new molecular concept was required for the analysis
of these experiments. This concept has to allow for
variations of Hill coefficients and is shown below.
Model development
Reversible binding of compound A to a receptor R
generally is described as:
A þ R !   AR ð3Þ
The receptor concept [6] states that activity is proportional
to the concentration of the occupied receptor AR. For
enzymes, activity is measured as the rate of product
formation, which itself is proportional to the concentration
of the enzyme–substrate complex AR and thus need not be
discussed separately. Structural studies had shown that
similar molecules which bind to the same site may find
different arrangements of microscopic interactions (H-bonds,
etc.) on the protein [12, 13]. Molecular dynamics of proteins
show that a binding site of a protein is by no means rigid. It
is therefore plausible to assume that there are binding patches
on a protein where compounds initially bind weakly to first
interaction points or to hydrophobic surfaces from where
they will find energetically more favored states involving
multiple interactions. If they do not dissociate during this
process, then 2-dimensional diffusion on those patches will
act like a funnel or an antenna, increasing the binding cross
section. For endogenous substrates, initial binding will lead
to stable binding at the active site and thus could only be
detected transiently. This need not be the case for inhibitors,
in particular not for those which are no transition state
analogues. Some may have a higher affinity toward the
initial patches; some may show multiple binding there.
Inhibition would be observed when binding patches involved
in substrate binding are occupied with inhibitors.
Figure 2 illustrates such a molecular model: An agonist
may bind transiently to binding patches (green or red) on
the receptor but will eventually bind to the active site
(blue). Different inhibitors may interact with any of those
patches and/or with the active site. In general, all inhibitors
I would bind to those patches on a protein R just as they
would bind to distinct sites:
R þ I !   RI; RI þ I !   RI2; ... RIn 1 ðÞ þ I !   RIn ð4Þ
Note that complexes RI, RI2,R I 3… will generally not be
unique, but will be dynamic ensembles where the com-
pounds may be bound to different locations and with
different numbers of microscopic interactions (hydrogen
bonds, etc.). Such transient states are only relevant for the
analysis of kinetic experiments. For the calculations of
equilibrium dose–response curves, however, the only valid
difference between complexes is the number of bound
inhibitor molecules I. Unlike for the classical models with
fixed sites, one need not consider a finite number of
arrangements (or the statistical degeneracy, as it is
sometimes called for equivalent sites) for such a dynamic
distribution. Nota bene: For n equivalent fixed sites with
intrinsic equilibrium dissociation constants KDi, such a
statistical degeneracy would correspond to
KDi ¼ n   i þ 1 ðÞ =i ðÞ   KD i ðÞ ð 5Þ
where KD(i) would denote the equilibrium dissociation
constants of scheme 4. Equation 5 is not required for
dynamic ensembles and is given here only for reference.
Reaction schemes 3 and 4 are sufficient to calculate
competitive binding models. More general mechanisms
should also consider binding of inhibitors to the protein–
substrate complex AR:
AR þ I !   ARI; ARI þ I !   ARI2; ::: ARIn 1 þ I !   ARIn ð6Þ
These mixed complexes of substrate, receptor, and
inhibitor again need not be static but will be ensembles
only characterized by the number of bound small com-
pounds. Ternary complexes ARIi may be active when
inhibitors do not interfere with the mechanism or may be
inactive for uncompetitive inhibitors. Employing schemes
3–5 for curve fitting would require 2×n equilibrium
Fig. 2 Molecular model. A simplified molecular model of a receptor
R is drawn with one active site (blue) and two different binding
patches (green and red). The agonist A may initially bind with its
corresponding ‘side’ (green or red) to one binding patch. Diffusion
will lead to predominant binding to the active site (blue). Different
inhibitors (drugs drawn as green, blue,o rred) may be specific for the
active site (blue) but also for a corresponding binding patch (green or
red). Binding of agonist A and one type of inhibitors I to the receptor
R is illustrated for one possible complex ARI2. A classical model for
1:1 competition would be similar and simply would not consider
binding patches as drug targets
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plexes. Obviously, 3×n parameters cannot be determined
from 11 data points. Therefore, one has to make further
assumptions in order to reduce the number of parameters.
Plausible simplifications led to models C, N and A, as
described below.
Model C (Competitive binding) Binding of inhibitor is
calculated according to scheme 4. No mixed complexes of
enzyme, substrate, and inhibitor are considered. The
number of fitting parameters is reduced when the inter-
actions of inhibitors are generalized, postulating that the
affinity for the ith inhibitor depends on the affinity of the
(i–1)th inhibitor:
KD i ðÞ¼KD i   1 ðÞ =CIF ; CIF ¼ KD i   1 ðÞ =KD i ðÞ ð7Þ
With equilibrium dissociation constants KD(i)f o rt h e
respective steps. The compound interaction factor CIF
quantifies the interaction of inhibitors: For CIF=0, only
one inhibitor molecule can bind, and the stoichiometry of
inhibitor and substrate is 1:1. For 0<CIF<1, binding of
one inhibitor decreases the affinity for the next. CIF>1
indicates increase in affinity for subsequent binding steps.
This would require induced conformational changes of the
receptor or intermolecular interactions of bound inhibitors.
Note that the parameter CIF is not the same as the Hill
coefficient, and for CIF=1, model C corresponds to
classical “cooperative” binding, taking classical degener-
acy (5) into account. Model C only has four parameters for
curve fitting, namely KD(1) and the compound interaction
factor CIF, as well as Min and Max for adjusting
experimental variations.
Model N (Non-competitive binding) Binding of inhibitor is
calculated according to schemes 4 and 6. All ternary
complexes ARIi are inactive. The affinity of the inhibitor
for free and substrate-bound enzyme is assumed to be
identical. The generalized compound interaction 7 is
assumed to hold for schemes 4 and 6. Model N also
requires only four parameters, namely KD(1) and CIF as
well as Min and Max.
Model A (Active ARI) Binding of inhibitor is calculated
according to schemes 4 and 6. The first ternary complex
ARI is assumed to be fully active. All other complexes with
bound inhibitor are assumed to be inactive. The first
affinities of the inhibitor for free or substrate-bound enzyme
are different. The simplification 7 holds for schemes 4 and
6. Model A requires five parameters, namely KIA1=KD(1)
for scheme 4, and KIA2=KD(1) for scheme 5, CIF for the
interactions of inhibitors 7, as well as Min and Max.
Each of the schemes A, C, and N require a given
maximal number of bound inhibitors to fit the data. In
initial calculations, the number was varied between 2 and
8 but was set to 6 for most calculations shown below. This
is in the order of the highest Hill coefficients present in our
data and thus did not impose additional restrictions to curve
fitting. This number by no means indicates that there are six
well-defined inhibitor binding sites on these patches: Only
the agonist (substrate) binding site must be a well-defined
active site (Fig. 2).
Analyzing inhibition curves on the basis of molecular
models
Figure 3a shows enzymatic activity of VHR versus the
logarithm of inhibitor (compound 281) concentration
1.
For this figure, the standard phoshatase inhibitor bis(4-
trifluoromethylsulfonamidophenyl)-1,4-diisopropylbenzene
(CalBiochem, PTP Inhibitor IV) was selected. The data
were fitted to models A6, N6, and C6. In that notation, A,
N, and C denote the type of model, whereas the number
denotes the maximal number of inhibitors which are
considered. The solid green line (4PL) shows a four-
parameter fit (Eq. 1) and has a symmetric sigmoid type of
shape in this half-logarithmic representation. Note that the
experimental data are not symmetrical. At low concen-
trations (between 0.1 and 1 μM), the experimental data
show a slight decrease at a concentration range where the
4PL fit remains unchanged. At high concentrations (50 and
100 μM), the experimental data have reached their
minimum of 0% activity, whereas the 4PL fit still shows a
decrease. The (…-) dotted green line shows a theoretical
curve for 1:1 competition and IC50 from 4PL. Visual
inspection of this experiment does not allow one to
distinguish between the three models A6, N6, and C6.
All fitting routines try to minimize the sum of squares,
which is the sum of the squared difference from theoretical
to experimental values. The residual sum of squares is a
measure of the goodness of fit and can be used to compare
models. When the residual sum of squares simply was
averaged for all 1282 experiments, models A6, C6, and N6
gave smaller residuals (69%, 88%, and 87%, indicating
better fits) than the residuals of the four-parameter fit (taken
as 100%). Figure 4 shows relative residuals (relative to
4PL) as a function of the Hill coefficients. The experimen-
tal section describes the removal of outliers and smoothing,
leading to the error bars of Fig. 4. Since all residuals were
1 All parameters obtained from the fitting procedures for all
experiments are listed together with the corresponding residuals in
the table “FitANCH6” of the supplementary material. The experi-
ment of Fig. 3a can be identified with the N = 281 and quadrant 3, the
experiment of Fig. 3b with N = 172 and quadrant 2.
J Chem Biol (2008) 1:95–104 99calculated as percent of 4PL residuals, four-parameter fits
are represented by the solid line of 100% in Fig. 4. For nH>
1, models A6, N6, and C6 differed only within their
standard deviation, but all were significantly better than
4PL, the 100% value. For nH=1, the error bars are very
small (<5%). This does not indicate that the experiments
were less noisy in that range but that the calculated curves
of all models were identical to single-site competition. For
these curves, the parameter CIF fitted to the lower limit
(0.001) of the fitting routine and thus numerically ruled out
multiple binding in the models A6, N6, and C6. For Hill
coefficients nH<1, models C6 and N6 were not adequate to
fit the data.
An experiment with nH<1 is illustrated in Fig. 3b, fitting
the inhibition of VE-PTP activity with the inhibitor
epigallocatechin-3-monogallate (compound 172). Models
C6 and N6 gave identical bad fits, so that their curve
patterns were superimposed and gave the impression of one
sinusoidal-shaped line meandering around the data. Models
C6 and N6 therefore are not applicable for nH<1. Note that
the inhibitor concentration range was not sufficient to cover
the full range from 100% to 0% activity for inhibitors with
low Hill coefficients such as in Fig. 3b.
Some other models which were applied to fit the data
also should be mentioned. When models C2, C4, C6, and
C8 were fitted to experiments with nH>1, C2 could not fit
experiments with nH>1.5. C6 showed the lowest residual
sum of squares but only within the experimental error as
compared to C4 and C8. The fitted value of CIF decreased
with increasing numbers of inhibitors.
Multi-parameter fitting generally will give ambiguous
results when the parameters are correlated, that is, if an
increase of parameter 1 leads to the same effect as an
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Fig. 3 Dose–response curves. Phosphatase activity was measured at
37 °C in the presence of inhibitors as initial velocity and was related to
independent 100% and 0% controls. The resulting percent activity is
shown vs. inhibitor concentrations. The data were fitted to the four-
parameter logistic model (4PL) and to the models A6, N6, and C6.
a The phosphatase VHR was inhibited with compound 281. The Hill
coefficient was 2.7. Other parameters obtained from fitting are shown
in row 1,282 of table FitANCH6.xls of the supplementary material.
The green (…-) dotted line does not result from data fitting but
illustrates the case of simple competitive binding (C1), with IC50
taken from 4PL. Models A6, N6, and C6 could fit the data equally
well for Hill coefficients ≥1. b The phosphatase VE-PTP was
inhibited with compound 172. The Hill coefficient was 0.55. Other
parameters obtained from fitting are shown in row 1,182 of table
FitANCH6.xls of the supplementary material. Model A6 (not C6 or
N6) could fit the data when the Hill coefficient was significantly
smaller than 1
100 J Chem Biol (2008) 1:95–104increase of parameter 2. That correlation is quantified by
means of correlation coefficients [11] which would be 1 for
linear functions and 0 for independent parameters. For
independent fits or independent observations, high correla-
tion coefficients indicate a functional relation, whereas
correlation factors of 0 indicate no correlation. The
correlation coefficients for models A6, N6, C6, and 4PL
a r es h o w ni nT a b l e1. For example, the correlation
coefficient of 0.06 for IC50 and Hill coefficient indicates
no significant correlation. This is reflected in the dot plot of
Fig. 1, where indeed no correlation between these param-
eters is visible. The compound interaction factor CIF is
correlated to the Hill coefficient for all models. This
relation is shown in the dot plot of Fig. 5a for model C6.
It can be used to extrapolate the compound interaction
factor CIF from the Hill coefficient. If one would have
identified distinct sites, that plot can be used in conjunction
with Eq. 5 to calculate the average affinities for these sites.
Note that for Hill coefficient <1, the parameter CIF was
fitted to its lower limit of 0.001, indicating that the binding
of one inhibitor molecule effectively blocks the binding of a
second one. The compound interaction factors CIF and the
equilibrium dissociation constants KI(1) were correlated for
all models. This is illustrated for model C6 in Fig. 5b.
Parameters with a correlation coefficient of 0.67 are not
orthogonal and thus not ideal for curve fitting.
Multiple binding of inhibitors might be nonspecific and
might be related to general molecular properties like solubil-
ity, polarizability, or hydrogen bonds. However, when
correlation coefficients were determined, none of the param-
eters AlogP98,polarizability, pLC50,volume, hydrogenbond
(HB) donors, HB acceptors, or number of rings were
correlated to the Hill coefficient nH. Note that all experiments
were done in the presence of 0.0125 of the non-denaturing
detergent NP-40 in order to avoid hydrophobic unspecific
interactions leading to promiscuous binding [14].
Models A6, N6, and C6 alike predict multiple sequential
binding of inhibitor according to scheme 4. In order to
verify this prediction, binding of the well-known “PTP
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Fig. 5 Dot plots of selected parameters derived from data fitting
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compound interaction factor CIF from a known Hill coefficient.
b First KI(1) vs. CIF (Eq. 7), correlation coefficient 0.71. This plot
shows that both parameters are not independent
Table 1 Correlation coefficients for selected parameters obtained from non-linear fitting of 1,282 experiments (shown in FitANCH6 of the
supplementary material)
KIA1-A6 KIA2-A6 CIF-A6 KI1-N6 CIF-N6 KI1-C6 CIF-C6 IC50 nH
KIA1-A6 1 0.28 0.45 0.68 0.46 0.73 0.49 0.25 0.53
KIA2-A6 1 0.61 0.67 0.57 0.65 0.59 0.46 0.51
CIF-A6 1 0.67 0.97 0.69 0.98 0.11 0.96
KI1-N6 1 0.67 0.99 0.69 0.66 0.67
CIF-N6 1 0.68 0.99 0.13 0.95
KI1-C6 1 0.71 0.59 0.71
CIF-C6 1 0.13 0.96
IC50 1 0.06
nH 1
J Chem Biol (2008) 1:95–104 101Inhibitor IV” from CalBiohem (compound 281) to the
phosphatase VHR was measured directly by means of
isothermal titration calorimetry at 15 °C, 25 °C, and at
37 °C (Fig. 6). The buffer effect (dilution of the
corresponding amount of DMSO into buffer with deter-
gent) was subtracted but consisted of the same peak
between the second and the eighth injections, which is
visible in Fig. 6. The corresponding inhomogeneity in Fig. 6
therefore may be attributed to a dilution artifact. When the
equilibrium constants from model C6 of the competition
experiment in Fig. 3a were used to calculate the ITC
experiment (blue solid line), the fit was reasonable, at least
better than for a fit assuming two sites (green dotted line).
This is remarkable, since both experiments were done with
slightly different buffer and different charges of VHR and
compound 281. If all 12 parameters (six affinity constants
and six entropies) were allowed to vary, the fit was better
(red dashed line), although 12 parameters cannot be deduced
from that experiment. The obtained parameters are only
listed for reference in the supplementary material.
Discussion
The concept of inhibitor binding patches with transient non-
defined sites was translated into three molecular models for
reversible inhibitor binding. These models were successfully
employed to fit a consistent body of dose–response curves.
For Hill coefficients larger than one, a model of competitive
inhibition (C6) and a model of non-competitive inhibition
(N6) both gave better fits than the standard four-parameter fit
employing the same number of four parameters for the fitting
process. Dose–response curves obviously are not adequate
for the distinction between competitive and non-competitive
inhibition. Interactions of bound drugs with each other or
with the binding patch may lead to facilitated binding or
steric hindrance for inhibitors and/or to induced conforma-
tional changes of the target macromolecule. All this is
quantified as variations in the compound interaction factors
CIF. Similar reasoning extends to Hill coefficients smaller
than one, where different interactions may allow or prohibit
an active ternary complex ARI. For larger Hill coefficients,
all models predict multiple inhibitor binding with increasing
inhibitor concentration. This prediction was confirmed with
microcalorimetry. The concept of binding patches is not
based on mechanistic models of the phosphatases studied
here and therefore should be generally applicable.
Classical molecular mechanisms assume unique interac-
tions between inhibitor and enzyme. Competitive inhibition in
classicalmodelswouldindicatethattheinhibitorbindsexactly
to the substrate pocket and thus competes for that site [15].
This is plausible for 1:1 competition and, thus, for experi-
ments with Hill coefficients nH exactly equal to one. Any
experiment with Hill coefficient significantly other than one
violates 1:1 stoichiometry, no matter how small the deviation.
For binding curves with Hill coefficients larger than one,
allosteric models, such as for oxygen binding to hemoglobin
[16], had been applied. But how could one account for
variation in nH? Could one seriously imagine different
numbers of subunits interacting with different inhibitors
acting on the same enzyme? And even when one tries to
calculate formal schemes involving one, two, three, four,
five… sites as indicated from the distribution of Hill
coefficients in Fig. 1: How could it be that one inhibitor
fits to a specific mechanism involving the high number of
three (or four?) specific binding sites, whereas a similar
compound inhibits with a different stoichiometry? Answering
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Fig. 6 Isothermal titration calorimetry of 25 μM of the phosphatase
VHR with compound 281. A solution of 1 mM compound 281 was
titrated in 8 μl steps into a solution of VHR phosphatase at 37 °C. The
heat absorbed/released upon their interaction (ΔH) was monitored
over time (top panel). The heats from each injection is integrated and
plotted against the ratio of compound 281 and VHR phosphatase in
the cell (closed squares). These data were fitted with model C6 and
equilibrium constants from inhibition experiments (blue solid line), C6
without restriction (red dashed line), and model C2 (green dotted
line). The parameters obtained from the fitting procedures were
compiled in a table shown in the supplementary material. The binding
mechanism deduced indirectly from Fig. 3a thus could be confirmed
with direct measurements
102 J Chem Biol (2008) 1:95–104those questions for classical mechanisms may not be
impossible for single, well-defined cases [17] but would be
extremely difficult in the general case or even for the limited
set of experiments described here.
The concept of transient non-defined sites contradicts all
schemes where sites are an intrinsic feature of the molecular
mechanism [18–20]. It is, however, very similar to multiple
binding of calcium antagonists to the L-type calcium channel
[21]: Dihydropyridines are potent established and specific
drugs for the treatment of heart failure, yet at higher
concentrations they will act as local anesthetics and generally
block cationic ion channels. Conversely, local anesthetics
interact with dihydropyridine binding [22]. These mecha-
nisms are difficult to reconcile with classical inhibition and
led to the postulation of allosteric effects [23, 24]. The
underlying mechanism simply may be multiple binding to
transient overlapping patches, just as postulated here for
models N. Note that such a mechanism can be confirmed by
means of independent kinetic displacement experiments
when “accelerated” [25]o r“facilitated” [26] dissociation
would be expected.
Bioactive compounds seem to conform to certain
structural requirements which are common to natural
products and can be applied to “biology-oriented synthe-
sis” [7]. It is feasible that those bioactive compounds have
some general affinity towards proteins or patches on
proteins. In view of this, bioactive inhibitors may
generally bind to substrate binding patches of the protein
from where they would inhibit the active site specifically.
Any general binding step would increase the probability
for side effects. Following this reasoning, inhibitors with
high Hill coefficients should be scrutinized for pharmaco-
logical side effects.
In conclusion, the reaction scheme A þ R !   AR is a
simplification, when the binding of compounds to macro-
molecules is concerned. The simplification is justified for
natural substrates, when a stepwise association process
leads to a final bound state. This need not be the case for
non-endogenous compounds (drugs) which may well
interact with parts of the protein (patches) which are
involved in the association process of substrates, but which
need not be the active site. Whenever inhibition curves are
fitted with Hill coefficients larger than one, classical 1:1
competition for an active site can be ruled out, and multiple
drug (inhibitor) binding must be considered. Drug design
based on docking programs to the active site of a rigid
protein structure should only yield inhibitors (blue in
Fig. 2) which bind with Hill coefficients of 1. Flexible
docking programs such as MODOR [27] consider transient
molecular interactions of ligands with macromolecules and
thus allow the identification of binding patches and
corresponding inhibitors. Discrimination of molecular
inhibition mechanisms can be supported by Hill coeffi-
cients, which therefore should be published along with the
IC50 values for high throughput screens.
Acknowledgements We thank Roger Goody (Max-Planck-Institute
Dortmund) for helpful in-depth discussions of the molecular models
and Wipa Suginta (Suranaree University of Technology) for reading
and discussing the manuscript. We thank Herbert Waldmann (Max-
Planck-Institute Dortmund) and the chemists in his department for
providing a library of specific phosphatase inhibitors, Dietmar
Vestweber (Max-Planck-Institute Münster) for donating VE-PTP,
Harald Schwalbe (Univ. Frakfurt) for donating PTP1b, MPTPA,
MPTPB and SHP-2, and Kirill Alexandrov (Max-Planck-Institute
Dortmund) for providing VHR and CDC25a. We thank Heike Rimpel
(Max-Planck-Institute Dortmund) for carrying out the screening
experiments and Jürgen Huber (Max-Planck-Institute Dortmund) for
writing the data collection software. Author contributions: Heino Prinz
built up the automated screening facility, developed the molecular
concept and analysis programs, performed model calculations, and
wrote the manuscript. André Schönichen performed all calorimetric
experiments and the corresponding analysis. The screening project
was supported by the Zentrum für Angewandte Chemische Genomik,
a joint research initiative founded by the European Union (“Euro-
päischer Fond für regionale Entwicklung”) and the state of North
Rhine-Westfalia.
References
1. Drews J (2000) Drug discovery: a historical perspective. Science
287:1960–1964
2. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP,
Auld DS (2007) High-throughput screening assays for the
identification of chemical probes. Nat Chem Biol 3:466–479
3. National Institutes of Health Chemical Genomics Center guidelines
(2008)http://www.ncgc.nih.gov/guidance/section3.html (July, 2008)
4. Hill AV (1910) The possible effects of the aggregation of the
molecules of haemoglobin on its dissociation curves. J Physiol
(Lond) 40:iv–vii
5. Weiss JN (1997) The Hill equation revisited: uses and misuses.
FASEB J 11:835–841
6. Langley JN (1905) On the reaction of cells and of nerve-endings
to certain poisons, chiefly as regards the reaction of striated
muscle to nicotine and to curare. J Physiol 33:374–413
7. Noren-Muller A, Reis-Correa I Jr, Prinz H, Rosenbaum C, Saxena
K, Schwalbe HJ, Vestweber D, Cagna G, Schunk S, Schwarz O,
Schiewe H, Waldmann H (2006) Discovery of protein phospha-
tase inhibitor classes by biology-oriented synthesis. Proc Natl
Acad USA 103:10606–10611
8. Manger M, Scheck M, Prinz H, von Kries JP, Langer T, Saxena K,
Schwalbe H, Furstner A, Rademann J, Waldmann H (2005)
Discovery of Mycobacterium tuberculosis protein tyrosine phos-
phatase A (MptpA) inhibitors based on natural products and a
fragment-based approach. Chembiochem 6:1749–1753
9. Copeland RA (2003) Mechanistic considerations in high-through-
put screening. Anal Biochem 320:1–12
10. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical
parameter for use in evaluation and validation of high throughput
screening assays. J Biomol Screen 4:67–73
11. Correlation coefficients in http://en.wikipedia.org/wiki/Correlation_
coefficient (July 2008) based on: Fisher RA (1915) Frequency
distribution of the values of the correlation coefficient in
samples from an indefinitely large population. Biometrika
10:507–521
J Chem Biol (2008) 1:95–104 10312. Andersen OA, Nathubhai A, Dixon MJ, Eggleston IM, van Aalten
DMF (2008) Structure-based dissection of the natural product
cyclopentapeptide chitinase inhibitor argifin. Chem Biol 15:295–301
13. Prinz H (2008) How to identify a pharmacophore. Chem Biol
15:207–208
14. Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK ( 2005)
High-throughput assays for promiscuous inhibitors. Nat Chem
Biol 1:146–148
15. Wang Z-X (1995) An exact mathematical expression for describ-
ing competitive binding of two different ligands to a protein
molecule. FEBS Lett 360:111–114
16. Monod J, Wyman J, Changeux J-P (1965) On the nature of
allosteric transitions: a plausible model. J Mol Biol 12:88–118
17. Grant GA (2004) Methods for analyzing cooperativity in phospho-
glycerate dehydrogenase. Methods Enzymol 380:106–121
18. Prinz H (1992) Receptor-binding kinetics. In: Hulme EC (ed)
Receptor-ligand interactions. A practical approach. Oxford Uni-
versity Press, Oxford, pp 265–288.H
19. Prinz H, Maelicke A (1986) Quantitative analysis of receptor-
ligand interactions at equilibrium. J Biol Chem 261:14962–
14964
20. Prinz H, Maelicke A (1992) Ligand binding to the membrane-
bound acetylcholine receptor from Torpedo marmorata: a com-
plete mathematical analysis. Biochemistry 31:6728–6738
21. Berger W, Prinz H, Striessnig J, Kang H-C, Haugland R,
Glossmann H (1994) Complex molecular mechanism for dihy-
dropyridine binding to L-type Ca
2+-channels as revealed by
fluorescence resonance energy transfer. Biochemistry 33:11875–
11883
22. Bolger GT, Marcus KA, Daly JW, Skolnick P (1987) Local
anesthetics differentiate dihydropyridine calcium antagonist bind-
ing sites in rat brain and cardiac membranes. J Pharmacol Exp
Ther 240:922–930
23. Staudinger R, Knaus HG, Glossmann H (1991) Positive hetero-
tropic allosteric regulators of dihydropyridine binding increase the
Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal
by the novel Ca2+ antagonist BM 20.1140. J Biol Chem
266:10787–10795
24. Marks TN, Jones SW (1992) Calcium currents in the A7r5 smooth
muscle-derived cell line. An allosteric model for calcium channel
activation and dihydropyridine agonist action. J Gen Physiol
99:367–390
25. Prinz H, Striessnig J (1993) Ligand-induced accelerated dissoci-
ation of (+)-cis-diltiazem from L-type Ca
2+ channels is simply
explained by competition for individual attachment points. J Biol
Chem 268:18580–18585
26. Gutfreund H (1995) Kinetics for the life sciences: receptors,
transmitters and catalysts. Cambridge University Press, Cam-
bridge, p 194
27. Description of MODOR, a flexible docking program http://
mondale.ucsf.edu/index_mordor.html (July, 2008) based on Guil-
bert C and Perahia D (1995) A method to explore transition paths
in macromolecules. Applications to phosphoglycerate kinase and
hemoglobin. Comput Phys commun 91:263–273
104 J Chem Biol (2008) 1:95–104